Larry Mimms, Ph.D.
CEO, ProciseDx
Dr. Mimms is currently CEO of ProciseDx in San Diego. He was Chief Scientific Officer at Prometheus Laboratories (2015 to 2019). From 2009 to 2015, Dr. Mimms served as Vice President R&D Quidel Corp., a world leader in development of point of care, rapid tests. He also teaches a course at UCSD Extension on in vitro diagnostic product development around which a certification program has been developed. Prior to his work at Quidel, Dr. Mimms founded VDx LLC in 2008 to develop rapid, point of care HIV diagnostic tests.
From 1994 to 2007 Dr. Mimms held a number of Executive positions at Gen-Probe Incorporated including Executive Vice President, Research and Development from 2005-2007 and Vice President, Development, Blood and Vice President of Strategic Planning and Business Development. Dr. Mimms initiated and headed up the Gen-Probe blood bank program from 1996 to 2002. In 1996, he and his colleagues won a National Institutes of Health (NIH) contract to develop blood screening assays to detect HIV and HCV nucleic acid. This work and later contracts led to FDA licensure and market introduction of Procleix HIV-1/HCV, Ultrio HIV-1/HCV/HBV assay and the Procleix West Nile Virus assay. As a result of this work, Gen-Probe won the 2004 National Medal of Technology, the highest U.S. honor for technological innovation, for “development and commercialization of new blood testing technologies and systems for the direct detection of viral diseases.” Dr Mimms served as a member of the Blue Ribbon R&D Panel for the American Red Cross from 2006-2007.
Prior to Joining Gen-Probe, Dr, Mimms held various positions in the Hepatitis/AIDS Business Unit at Abbott Laboratories. He was an NIH Postdoctoral Fellow at Harvard University in Cellular and Developmental Biology prior to joining Abbott Laboratories. He earned a Ph.D. in biochemistry from Duke University and a B.S. in chemistry from Davidson College. In 2014 Dr. Mimms received an honorary doctorate in science from Davidson College for his work on HIV, HCV and HBV. Dr. Mimms was awarded the 2017AACC Edwin F. Ullman Award for Technology Innovation.
